Intech Biopharm Ltd Statistics
Intech Biopharm Ltd (6461) Stock Statistics & Valuation Metrics
Total Valuation
Intech Biopharm Ltd has a market cap or net worth of TWD 2.95B. The enterprise value is TWD 3.80B.
- Market Cap
- TWD 2.95B
- Enterprise Value
- TWD 3.80B
Share Statistics
Intech Biopharm Ltd has 110,324,524 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 110,324,524
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Intech Biopharm Ltd’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is -15.84%.
- Return on Equity (ROE)
- -0.35
- Return on Assets (ROA)
- -0.17
- Return on Invested Capital (ROIC)
- -15.84%
- Return on Capital Employed (ROCE)
- -0.17
- Revenue Per Employee
- 1.12M
- Profits Per Employee
- -4.05M
- Employee Count
- 96
- Asset Turnover
- 0.05
- Inventory Turnover
- 1.95
Valuation Ratios
The current PE Ratio of Intech Biopharm Ltd is -5.81. Intech Biopharm Ltd’s PEG ratio is 0.31.
- PE Ratio
- -5.81
- PS Ratio
- 59.54
- PB Ratio
- 3.14
- Price to FCF
- -6.90
- Price to Operating Cash Flow
- -7.53
- PEG Ratio
- 0.31
Income Statement
In the last 12 months, Intech Biopharm Ltd had revenue of 107.53M and earned -389.03M in profits. Earnings per share was -4.14.
- Revenue
- 107.53M
- Gross Profit
- -120.12M
- Operating Income
- -364.50M
- Pretax Income
- -382.23M
- Net Income
- -389.03M
- EBITDA
- -273.24M
- Earnings Per Share (EPS)
- -4.14
Cash Flow
In the last 12 months, operating cash flow was -372.70M and capital expenditures -46.45M, giving a free cash flow of -419.15M billion.
- Operating Cash Flow
- -372.70M
- Free Cash Flow
- -419.15M
- Free Cash Flow per Share
- -3.91
Dividends & Yields
Intech Biopharm Ltd pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -14.53%
- Earnings Yield
- -17.20%
Stock Price Statistics
- Beta
- 0.66
- 52-Week Price Change
- 3.23%
- 50-Day Moving Average
- 26.53
- 200-Day Moving Average
- 28.05
- Relative Strength Index (RSI)
- 47.23
- Average Volume (3m)
- 111.97K
Important Dates
Intech Biopharm Ltd upcoming earnings date is Mar 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 06, 2026
- Next Earnings Date
- Mar 17, 2027
- Ex-Dividend Date
- ―
Financial Position
Intech Biopharm Ltd as a current ratio of 1.66, with Debt / Equity ratio of 107.96%
- Current Ratio
- 1.66
- Quick Ratio
- 1.18
- Debt to Market Cap
- 0.44
- Net Debt to EBITDA
- -4.29
- Interest Coverage Ratio
- -10.87
Taxes
In the past 12 months, Intech Biopharm Ltd has paid 6.80M in taxes.
- Income Tax
- 6.80M
- Effective Tax Rate
- -0.02
Enterprise Valuation
Intech Biopharm Ltd EV to EBITDA ratio is -11.17, with an EV/FCF ratio of -9.82.
- EV to Sales
- 84.82
- EV to EBITDA
- -11.17
- EV to Free Cash Flow
- -9.82
- EV to Operating Cash Flow
- -11.05
Balance Sheet
Intech Biopharm Ltd has TWD 145.42M in cash and marketable securities with TWD 1.33B in debt, giving a net cash position of -TWD 1.18B billion.
- Cash & Marketable Securities
- TWD 145.42M
- Total Debt
- TWD 1.33B
- Net Cash
- -TWD 1.18B
- Net Cash Per Share
- -TWD 10.72
- Tangible Book Value Per Share
- TWD 8.30
Margins
Gross margin is -396.01%, with operating margin of -957.88%, and net profit margin of -992.81%.
- Gross Margin
- -396.01%
- Operating Margin
- -957.88%
- Pretax Margin
- -992.81%
- Net Profit Margin
- -992.81%
- EBITDA Margin
- -759.48%
- EBIT Margin
- -948.41%
Analyst Forecast
The average price target for Intech Biopharm Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -57.87%
- EPS Growth Forecast
- -21.67%
